ClinicalTrials.gg
CompletedNCT02796131Updated Jun 10, 2016

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

A Phase 1 interventional study of RDX5791 and Placebo in Healthy, sponsored by Ardelyx. Completed. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-10.

Sponsored by Ardelyx · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerabiltiy, and pharmacodynamics of different multiple dose regimens of RDX5791 in healthy volunteers.

Read the detailed description

The starting doses for this study are based on the results from the multiple ascending-dose study performed on RDX5791 (Protocol RDX5791-101). Subjects will be screened within 3 weeks of check in to the CPU. Each cohort of 15 subjects (12 RDX5791, 3 placebo) will check in to the CPU on Day -5 before dinner. Each subject will receive a diet standardized for Na+ content while in the CPU. Subjects will receive doses of RDX5791 with approximately 240 mL of non-carbonated water on Days 1 to 7 (just prior to meals, depending on QD, bid, or tid regimens). Subjects will be provided standardized meals within 10 minutes after dosing. Doses can be administered with breakfast, lunch, or dinner.

02

Conditions studied

  • Healthy

Keywords

  • Phase I
  • Healthy
  • Pharmacodynamics
03

In context

Lead sponsor

Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 29.9 kg/m², inclusive
  • No abnormalities in medical history
  • Females must be non-pregnant, non-lactating, and either for at least 12 months or have agreed to use an effective form of from the time of signing the until 45 days after end of study
  • Men must be either sterile, abstinent, or agreed to use an approved method of contraception from check-in until 45 days after final study visit

Exclusion criteria

Exclusion Criteria:

  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract
  • Any surgery on the small intestine or colon, excluding appendectomy
  • Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days
  • Hepatic dysfunction ([] or [AST]) >1.5 times the or renal impairment
  • Any evidence of or treatment of , excluding non-melanomatous malignancies of the skin
  • Use of diuretic medications, medications that are known to affect stool consistency and/or GI motility
  • Use of an agent within 30 days prior to Day -2
  • Positive virology, alcohol, or drugs of abuse test during screening
  • Use of any prescription medication within 7 days before admission to the CPU
  • Have had significant blood loss (>450 mL) or have donated 1 or more units of blood or plasma within 8 weeks prior to study entry
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    30 mg bid

    30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    30 mg tid

    30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    60 mg bid

    60 mg of RDX5791 administered two times daily (120 mg total dose/day).

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    15 mg bid

    15 mg of RDX5791 administered two times daily (30 mg total dose/day).

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    30 mg QD

    30 mg of RDX5791 administered once daily (30 mg total dose/day).

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    Escalating dose bid

    15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.

    Drug: RDX5791 · Drug: Placebo

  • Experimental
    30 mg bid with psyllium

    30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).

    Drug: RDX5791 · Drug: Placebo

Interventions

  • Also known as: Tenapanor, AZD1722

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety of different dosing regimens of RDX5791

    Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams.

    Time frame: 7 Days

Secondary outcomes

  1. Pharmacodynamics of different dosing regimens of RDX5791

    Pharmacodynamics of different dosing regimens of RDX5791 will be assessed by bowel movement timing, consistency, frequency, and by urine and stool sodium (Na+) excretion.

    Time frame: 7 Days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clin Drug Investig. 2018 Apr;38(4):341-351. doi: 10.1007/s40261-017-0614-0. PubMed 29363027 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Oct 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2016
First posted
Jun 10, 2016
Start
Jul 2011
Primary completionActual
Oct 2011
CompletionActual
Apr 2012
Last update
Jun 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02796131
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
Jul 2011
Primary completion
Oct 2011
Completion
Apr 2012
Last update
Jun 10, 2016

Study contacts

David P. Rosenbaum, Ph.D
study chair · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion